EP2398900A4 - INSULATED MONOCYTIC POPULATIONS AND ASSOCIATED THERAPEUTIC APPLICATIONS - Google Patents

INSULATED MONOCYTIC POPULATIONS AND ASSOCIATED THERAPEUTIC APPLICATIONS

Info

Publication number
EP2398900A4
EP2398900A4 EP10744061A EP10744061A EP2398900A4 EP 2398900 A4 EP2398900 A4 EP 2398900A4 EP 10744061 A EP10744061 A EP 10744061A EP 10744061 A EP10744061 A EP 10744061A EP 2398900 A4 EP2398900 A4 EP 2398900A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic applications
related therapeutic
monocyte populations
isolated monocyte
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10744061A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2398900A1 (en
Inventor
Martin Friedlander
Matthew R Ritter
Stacey K Moreno
Mohammad A El-Kalay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP2398900A1 publication Critical patent/EP2398900A1/en
Publication of EP2398900A4 publication Critical patent/EP2398900A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1497—Particle shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10744061A 2009-02-20 2010-02-19 INSULATED MONOCYTIC POPULATIONS AND ASSOCIATED THERAPEUTIC APPLICATIONS Withdrawn EP2398900A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20817309P 2009-02-20 2009-02-20
US28324409P 2009-11-30 2009-11-30
PCT/US2010/000477 WO2010096177A1 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Publications (2)

Publication Number Publication Date
EP2398900A1 EP2398900A1 (en) 2011-12-28
EP2398900A4 true EP2398900A4 (en) 2012-08-22

Family

ID=42634163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10744061A Withdrawn EP2398900A4 (en) 2009-02-20 2010-02-19 INSULATED MONOCYTIC POPULATIONS AND ASSOCIATED THERAPEUTIC APPLICATIONS

Country Status (11)

Country Link
EP (1) EP2398900A4 (ru)
JP (1) JP2012518407A (ru)
KR (1) KR20110123778A (ru)
CN (1) CN102317446A (ru)
AU (1) AU2010216374A1 (ru)
BR (1) BRPI1008392A2 (ru)
CA (1) CA2752679A1 (ru)
EA (1) EA201190109A1 (ru)
MX (1) MX2011008826A (ru)
WO (1) WO2010096177A1 (ru)
ZA (1) ZA201105869B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377273A (zh) * 2013-05-22 2016-03-02 耶达研究与发展公司 用于治疗眼睛疾病或病症的人类单核细胞亚群
KR101668462B1 (ko) * 2015-02-26 2016-10-24 충북대학교 산학협력단 혈액성분을 유효성분으로 포함하는 녹내장의 예방 또는 치료용 약제학적 조성물
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
CN114441419B (zh) * 2022-01-29 2022-11-22 杭州翔宇医学检验实验室有限公司 流式圈门方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
WO2008001380A2 (en) * 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718735A1 (en) * 2004-02-11 2006-11-08 Aldagen, Inc. Stem cell populations and methods of use
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
WO2008001380A2 (en) * 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUILAR EDITH ET AL: "OCULAR MODELS OF ANGIOGENESIS", METHODS IN ENZYMOLOGY ELSEVIER ACADEMIC PRESS INC, 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SERIES : METHODS IN ENZYMOLOGY (ISSN 0076-6879(PRINT)), 2008, pages 115 - 158, XP009160775 *
HAZIOT A ET AL: "SOLUBLE CD14 INHIBITS THE ACTIVATION OF MONOCYTES INDUCED BY LPS", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, A.R. LISS, NEW YORK, NY, US, 21 February 1992 (1992-02-21), pages 163, XP000775642, ISSN: 0733-1959 *
See also references of WO2010096177A1 *
SUMEGI ET AL: "Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 117, no. 3, 1 December 2005 (2005-12-01), pages 271 - 279, XP005226349, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2005.09.002 *

Also Published As

Publication number Publication date
BRPI1008392A2 (pt) 2015-08-25
CN102317446A (zh) 2012-01-11
KR20110123778A (ko) 2011-11-15
CA2752679A1 (en) 2010-08-26
WO2010096177A1 (en) 2010-08-26
EP2398900A1 (en) 2011-12-28
AU2010216374A1 (en) 2011-08-18
ZA201105869B (en) 2012-10-31
EA201190109A1 (ru) 2012-07-30
JP2012518407A (ja) 2012-08-16
MX2011008826A (es) 2011-11-02

Similar Documents

Publication Publication Date Title
ZA201204700B (en) Optimized endonucleases and uses thereof
EP2440051A4 (en) TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
GB0921731D0 (en) Theraputic uses
EP2422194A4 (en) VESICULAR SYSTEM AND USES THEREOF
GB0914644D0 (en) Novel agents and uses thereof
AU327667S (en) Chair
EP2499034A4 (en) WHEELCHAIR
ZA201106705B (en) Antiviral compounds and uses thereof
EP2440052A4 (en) TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
HK1167857A1 (en) Antiviral compounds and uses thereof
EP2491822A4 (en) CHAIR
PL2264358T3 (pl) Oprawa oświetleniowa i taśma oświetleniowa
IL214720A0 (en) Pyridocarbazole type compounds and applications thereof
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2399993A4 (en) STREPTAVIDINE HYPO-IMMUNOGEN AND USE THEREOF
GB2467994B (en) Diver-propulsion units
IL216831A (en) History of triazine and their medical applications
AU329662S (en) Chair
ZA201105869B (en) Isolated monocyte populations and related therapeutic applications
EP2440055A4 (en) STYRYLTRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
GB2468914B (en) Dividing systems and components thereof
GB0913717D0 (en) Portering chair
EP2427766A4 (en) HUMAN GENE FG01 AND ITS APPLICATIONS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RITTER, MATTHEW, R.

Inventor name: FRIEDLANDER, MARTIN

Inventor name: MORENO, STACEY, K.

Inventor name: EL-KALAY, MOHAMMAD, A.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120719

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 63/02 20060101ALI20120713BHEP

Ipc: C12N 5/0786 20100101AFI20120713BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20121121